{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,5]],"date-time":"2026-05-05T06:26:44Z","timestamp":1777962404822,"version":"3.51.4"},"reference-count":101,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2025,6,1]],"date-time":"2025-06-01T00:00:00Z","timestamp":1748736000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,6,1]],"date-time":"2025-06-01T00:00:00Z","timestamp":1748736000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,6,1]],"date-time":"2025-06-01T00:00:00Z","timestamp":1748736000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2025,6,1]],"date-time":"2025-06-01T00:00:00Z","timestamp":1748736000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2025,6,1]],"date-time":"2025-06-01T00:00:00Z","timestamp":1748736000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2025,6,1]],"date-time":"2025-06-01T00:00:00Z","timestamp":1748736000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2025,6,1]],"date-time":"2025-06-01T00:00:00Z","timestamp":1748736000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/100017962","name":"Jiangsu Commission of Health","doi-asserted-by":"publisher","award":["M2024059"],"award-info":[{"award-number":["M2024059"]}],"id":[{"id":"10.13039\/100017962","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Best Practice & Research Clinical Haematology"],"published-print":{"date-parts":[[2025,6]]},"DOI":"10.1016\/j.beha.2025.101632","type":"journal-article","created":{"date-parts":[[2025,5,15]],"date-time":"2025-05-15T11:12:44Z","timestamp":1747307564000},"page":"101632","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":3,"title":["Research progress of targeted BCMA CAR-T therapy for relapsed\/refractory multiple myeloma antigen-negative relapse"],"prefix":"10.1016","volume":"38","author":[{"given":"Lulu","family":"Kong","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kailin","family":"Xu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wei","family":"Chen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"5","key":"10.1016\/j.beha.2025.101632_bib1","doi-asserted-by":"crossref","first-page":"464","DOI":"10.1001\/jama.2022.0003","article-title":"Diagnosis and management of multiple myeloma: a review","volume":"327","author":"Andrew","year":"2022","journal-title":"JAMA"},{"issue":"8","key":"10.1016\/j.beha.2025.101632_bib2","doi-asserted-by":"crossref","first-page":"1319","DOI":"10.1016\/j.ccell.2024.07.002","article-title":"CAR T cell combination therapies to treat cancer","volume":"42","author":"Uslu","year":"2024","journal-title":"Cancer Cell"},{"issue":"13","key":"10.1016\/j.beha.2025.101632_bib3","doi-asserted-by":"crossref","first-page":"1597","DOI":"10.1200\/JCO-24-01730","article-title":"Comparison of standard-of-care idecabtagene vicleucel and Ciltacabtagene autoleucel in relapsed\/refractory multiple myeloma","volume":"43","author":"Doris","year":"2025","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.beha.2025.101632_bib4","doi-asserted-by":"crossref","first-page":"2267","DOI":"10.1200\/JCO.2018.77.8084","article-title":"T cells genetically modified to express an anti-B-cell maturation antigen chimeric antigen receptor cause remissions of poor-prognosis relapsed multiple myeloma","volume":"36","author":"Jennifer","year":"2018","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.beha.2025.101632_bib5","doi-asserted-by":"crossref","first-page":"1688","DOI":"10.1182\/blood-2016-04-711903","article-title":"T cells expressing an anti-B-cell maturation antigen chimeric antigen receptor cause remissions of multiple myeloma","volume":"128","author":"Syed","year":"2016","journal-title":"Blood"},{"key":"10.1016\/j.beha.2025.101632_bib6","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1038\/nature22395","article-title":"Therapeutic T cell engineering","volume":"545","author":"Sadelain","year":"2017","journal-title":"Nature"},{"issue":"10","key":"10.1016\/j.beha.2025.101632_bib7","doi-asserted-by":"crossref","first-page":"1219","DOI":"10.1158\/2159-8290.CD-18-0442","article-title":"Tumor antigen escape from CAR T-cell therapy","volume":"8","author":"Majzner","year":"2018","journal-title":"Cancer Discov"},{"issue":"1","key":"10.1016\/j.beha.2025.101632_bib8","doi-asserted-by":"crossref","first-page":"1824","DOI":"10.1038\/s41467-025-56486-6","article-title":"Deciphering response dynamics and treatment resistance from circulating tumor DNA after CAR T-cells in multiple myeloma","volume":"16","author":"Hitomi","year":"2025","journal-title":"Nat Commun"},{"issue":"7","key":"10.1016\/j.beha.2025.101632_bib9","doi-asserted-by":"crossref","first-page":"1109","DOI":"10.1016\/j.bbmt.2013.04.025","article-title":"Molecular monitoring of minimal residual disease in the peripheral blood of patients with multiple myeloma","volume":"19","author":"Mark","year":"2013","journal-title":"Biol Blood Marrow Transplant"},{"issue":"20","key":"10.1016\/j.beha.2025.101632_bib10","doi-asserted-by":"crossref","first-page":"6178","DOI":"10.1182\/bloodadvances.2023010410","article-title":"Combining BCMA-targeting CAR T cells with TCR-engineered T-cell therapy to prevent immune escape of multiple myeloma","volume":"7","author":"Tassilo","year":"2023","journal-title":"Blood Adv"},{"issue":"Supple 1","key":"10.1016\/j.beha.2025.101632_bib11","article-title":"Normalization of the immune microenvironment during lenalidomide maintenance is associated with sustained MRD negativity in patients with multiple myeloma","volume":"138","author":"Coffey","year":"2021","journal-title":"Blood"},{"issue":"6","key":"10.1016\/j.beha.2025.101632_bib12","first-page":"2210","article-title":"B cell maturation antigen-specific CAR T cells are clinically active in multiple myeloma","volume":"129","author":"Adam","year":"2019"},{"issue":"1","key":"10.1016\/j.beha.2025.101632_bib13","doi-asserted-by":"crossref","first-page":"868","DOI":"10.1038\/s41467-021-21177-5","article-title":"Biallelic loss of BCMA as a resistance mechanism to CAR T cell therapy in a patient with multiple myeloma","volume":"12","author":"Mehmet","year":"2021","journal-title":"Nat Commun"},{"issue":"4","key":"10.1016\/j.beha.2025.101632_bib14","doi-asserted-by":"crossref","first-page":"1069","DOI":"10.1007\/s00277-023-05444-7","article-title":"BCMA-targeting chimeric antigen receptor T cell therapy for relapsed and\/or refractory multiple myeloma","volume":"103","author":"Fang","year":"2024","journal-title":"Ann Hematol"},{"issue":"6","key":"10.1016\/j.beha.2025.101632_bib15","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1038\/s41408-021-00507-2","article-title":"KarMMa-RW: comparison of idecabtagene vicleucel with real-world outcomes in relapsed and refractory multiple myeloma","volume":"11","author":"Jagannath","year":"2021","journal-title":"Blood Cancer J"},{"issue":"4","key":"10.1016\/j.beha.2025.101632_bib16","doi-asserted-by":"crossref","first-page":"402","DOI":"10.1182\/blood.2023023557","article-title":"Antigen escape as a shared mechanism of resistance to BCMA-directed therapies in multiple myeloma","volume":"144","author":"Ross","year":"2024","journal-title":"Blood"},{"issue":"18","key":"10.1016\/j.beha.2025.101632_bib17","article-title":"Overcoming antigen escape and T-cell exhaustion in CAR-T therapy for leukemia","volume":"13","author":"El\u017cbieta","year":"2024","journal-title":"Cells"},{"key":"10.1016\/j.beha.2025.101632_bib18","article-title":"Antigen escape in CAR-T cell therapy: mechanisms and overcoming strategies","volume":"178","author":"Haolong","year":"2024","journal-title":"Biomed Pharmacother"},{"issue":"4","key":"10.1016\/j.beha.2025.101632_bib19","doi-asserted-by":"crossref","first-page":"1642","DOI":"10.1016\/j.ymthe.2025.02.035","article-title":"CAR-mediated target recognition limits TCR-mediated target recognition of TCR- and CAR-dual-receptor-edited T cells","volume":"33","author":"Tassilo","year":"2025","journal-title":"Mol Ther"},{"key":"10.1016\/j.beha.2025.101632_bib20","doi-asserted-by":"crossref","first-page":"2210","DOI":"10.1172\/JCI126397","article-title":"B cell maturation antigen\u2013specific CAR T cells are clinically active in multiple myeloma","volume":"129","author":"Adam","year":"2019","journal-title":"J Clin Investig"},{"key":"10.1016\/j.beha.2025.101632_bib21","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2024.1433774","article-title":"Mechanisms and salvage treatments in patients with multiple myeloma relapsed post-BCMA CAR-T cell therapy","volume":"15","author":"Fu","year":"2024","journal-title":"Front Immunol"},{"issue":"10","key":"10.1016\/j.beha.2025.101632_bib22","doi-asserted-by":"crossref","first-page":"1421","DOI":"10.1158\/2326-6066.CIR-24-0061","article-title":"NK receptor signaling lowers TCR activation threshold, enhancing selective recognition of cancer cells by TAA-specific CTLs","volume":"12","author":"Bowen","year":"2024","journal-title":"Cancer Immunol Res"},{"issue":"8","key":"10.1016\/j.beha.2025.101632_bib23","doi-asserted-by":"crossref","first-page":"705","DOI":"10.1056\/NEJMoa2024850","article-title":"Idecabtagene vicleucel in relapsed and refractory multiple myeloma","volume":"384","author":"Nikhil","year":"2021","journal-title":"N Engl J Med"},{"issue":"2","key":"10.1016\/j.beha.2025.101632_bib24","doi-asserted-by":"crossref","first-page":"220","DOI":"10.1182\/blood.2024025231","article-title":"Single-cell analysis of the multiple myeloma microenvironment after \u03b3-secretase inhibition and CAR T-cell therapy","volume":"145","author":"David","year":"2025","journal-title":"Blood"},{"issue":"9","key":"10.1016\/j.beha.2025.101632_bib25","doi-asserted-by":"crossref","first-page":"2295","DOI":"10.1038\/s41591-023-02491-5","article-title":"Mechanisms of antigen escape from BCMA- or GPRC5D-targeted immunotherapies in multiple myeloma","volume":"29","author":"Holly","year":"2023","journal-title":"Nat Med"},{"issue":"13","key":"10.1016\/j.beha.2025.101632_bib26","doi-asserted-by":"crossref","first-page":"1211","DOI":"10.1182\/blood.2023022499","article-title":"BCMA- or GPRC5D-targeting bispecific antibodies in multiple myeloma: efficacy, safety, and resistance mechanisms","volume":"143","author":"Holly","year":"2024","journal-title":"Blood"},{"issue":"19","key":"10.1016\/j.beha.2025.101632_bib27","doi-asserted-by":"crossref","first-page":"1585","DOI":"10.1182\/blood.2019000050","article-title":"\u03b3-Secretase inhibition increases efficacy of BCMA-specific chimeric antigen receptor T cells in multiple myeloma","volume":"134","author":"Margot","year":"2019","journal-title":"Blood"},{"issue":"8","key":"10.1016\/j.beha.2025.101632_bib28","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1038\/s41408-022-00716-3","article-title":"\u03b3-secretase inhibitors augment efficacy of BCMA-targeting bispecific antibodies against multiple myeloma cells without impairing T-cell activation and differentiation","volume":"12","author":"Hailin","year":"2022","journal-title":"Blood Cancer J"},{"issue":"1","key":"10.1016\/j.beha.2025.101632_bib29","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1186\/s12943-023-01894-9","article-title":"Outsmarting trogocytosis to boost CAR NK\/T cell therapy","volume":"22","author":"Faezeh","year":"2023","journal-title":"Mol Cancer"},{"issue":"1","key":"10.1016\/j.beha.2025.101632_bib30","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1038\/s41392-023-01708-w","article-title":"Trogocytosis of CAR molecule regulates CAR-T cell dysfunction and tumor antigen escape","volume":"8","author":"Zhai","year":"2023","journal-title":"Signal Transduct Targeted Ther"},{"issue":"9","key":"10.1016\/j.beha.2025.101632_bib31","doi-asserted-by":"crossref","first-page":"1658","DOI":"10.4161\/onci.22032","article-title":"Trogocytosis generates acquired regulatory T cells adding further complexity to the dysfunctional immune response in multiple myeloma","volume":"1","author":"Ross","year":"2012","journal-title":"OncoImmunology"},{"issue":"Supple 1","key":"10.1016\/j.beha.2025.101632_bib32","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1182\/blood-2020-142130","article-title":"Describing the cellular and humoral immune tumor microenvironment and malignant transcriptome across the multiple myeloma disease spectrum","volume":"136","author":"Visram","year":"2020","journal-title":"Blood"},{"key":"10.1016\/j.beha.2025.101632_bib33","first-page":"7","article-title":"Decoding DNA methylation in epigenetics of multiple myeloma","author":"Ting","year":"2022","journal-title":"Blood Rev"},{"issue":"1","key":"10.1016\/j.beha.2025.101632_bib34","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1002\/cyto.b.21265","article-title":"Immunophenotype of normal vs. myeloma plasma cells: toward antibody panel specifications for MRD detection in multiple myeloma","volume":"90","author":"Juan","year":"2016","journal-title":"Cytometry B Clin Cytom"},{"issue":"3","key":"10.1016\/j.beha.2025.101632_bib35","doi-asserted-by":"crossref","first-page":"716","DOI":"10.1016\/j.immuni.2025.02.006","article-title":"Antigenic drift expands influenza viral escape pathways from recalled humoral immunity","volume":"58","author":"Daniel","year":"2025","journal-title":"Immunity"},{"issue":"Supple 1","key":"10.1016\/j.beha.2025.101632_bib36","article-title":"Timing antigenic escape in multiple myeloma treated with T-cell redirecting immunotherapies","volume":"144","author":"Marios","year":"2024","journal-title":"Blood"},{"key":"10.1016\/j.beha.2025.101632_bib37","article-title":"Ciltacabtagene autoleucel: the second anti-BCMA CAR T-cell therapeutic armamentarium of relapsed or refractory multiple myeloma","volume":"13","author":"Endeshaw","year":"2022","journal-title":"Front Immunol"},{"issue":"11","key":"10.1016\/j.beha.2025.101632_bib38","doi-asserted-by":"crossref","first-page":"2952","DOI":"10.1182\/bloodadvances.2023012354","article-title":"Mechanisms of resistance to bispecific T-cell engagers in multiple myeloma and their clinical implications","volume":"8","author":"Eric","year":"2024","journal-title":"Blood Adv"},{"issue":"29","key":"10.1016\/j.beha.2025.101632_bib39","article-title":"Unique and redundant roles of mouse BCMA, TACI, BAFF, APRIL, and IL-6 in supporting antibody-producing cells in different tissues","volume":"121","author":"Mahya","year":"2024","journal-title":"Proc. Natl. Acad. Sci. U.S.A"},{"issue":"12","key":"10.1016\/j.beha.2025.101632_bib40","doi-asserted-by":"crossref","first-page":"1365","DOI":"10.1038\/s41417-020-00284-3","article-title":"Overcoming target epitope masking resistance that can occur on low-antigen-expresser AML blasts after IL-1RAP chimeric antigen receptor T cell therapy using the inducible caspase 9 suicide gene safety switch","volume":"28","author":"Walid","year":"2021","journal-title":"Cancer Gene Ther"},{"issue":"1","key":"10.1016\/j.beha.2025.101632_bib41","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1186\/s13045-021-01209-9","article-title":"Born to survive: how cancer cells resist CAR T cell therapy","volume":"14","author":"Jean","year":"2021","journal-title":"J Hematol Oncol"},{"issue":"1","key":"10.1016\/j.beha.2025.101632_bib42","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1016\/j.kint.2019.01.031","article-title":"A Proliferation Inducing Ligand (APRIL) targeted antibody is a safe and effective treatment of murine IgA nephropathy","volume":"96","author":"James","year":"2019","journal-title":"Kidney Int"},{"issue":"4","key":"10.1016\/j.beha.2025.101632_bib43","doi-asserted-by":"crossref","first-page":"727","DOI":"10.1002\/ajh.27225","article-title":"Soluble B-cell maturation antigen in multiple myeloma","volume":"99","author":"Bruno","year":"2024","journal-title":"Am J Hematol"},{"issue":"7","key":"10.1016\/j.beha.2025.101632_bib44","doi-asserted-by":"crossref","first-page":"2089","DOI":"10.1016\/j.ymthe.2023.03.020","article-title":"Dual targeting of CD19 and CD22 against B-ALL using a novel high-sensitivity aCD22 CAR","volume":"31","author":"Evangelia","year":"2023","journal-title":"Mol Ther"},{"issue":"Supple 1","key":"10.1016\/j.beha.2025.101632_bib45","article-title":"The impact of prior treatment with a CD19 targeting monoclonal antibody on subsequent treatment with CD19 targeting CART cell therapy in preclinical models","volume":"138","author":"Sakemura","year":"2021","journal-title":"Blood"},{"issue":"4","key":"10.1016\/j.beha.2025.101632_bib46","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1038\/s41408-021-00459-7","article-title":"CAR-T cell therapy: current limitations and potential strategies","volume":"11","author":"Robert","year":"2021","journal-title":"Blood Cancer J"},{"issue":"5","key":"10.1016\/j.beha.2025.101632_bib47","doi-asserted-by":"crossref","first-page":"1649","DOI":"10.1111\/bjh.19348","article-title":"The role of chimeric antigen receptor T cells targeting more than one antigen in the treatment of B-cell malignancies","volume":"204","author":"Helena","year":"2024","journal-title":"Br J Haematol"},{"key":"10.1016\/j.beha.2025.101632_bib48","article-title":"CAR-T cells in the treatment of multiple myeloma: an encouraging cell therapy","volume":"16","author":"Tong","year":"2025","journal-title":"Front Immunol"},{"issue":"2","key":"10.1016\/j.beha.2025.101632_bib49","doi-asserted-by":"crossref","first-page":"214","DOI":"10.1016\/j.coi.2012.12.003","article-title":"T cell anergy, exhaustion, senescence, and stemness in the tumor microenvironment","volume":"25","author":"Joel","year":"2013","journal-title":"Curr Opin Immunol"},{"key":"10.1016\/j.beha.2025.101632_bib50","article-title":"CD19 -targeted CAR T therapy treating hematologic malignancies: hidden danger is the next neighbor to security?","volume":"16","author":"Ye","year":"2025","journal-title":"Front Immunol"},{"issue":"Supple 1","key":"10.1016\/j.beha.2025.101632_bib51","article-title":"GPRC5D status impacts CD38 expression in multiple myeloma","volume":"144","author":"Munawar","year":"2024","journal-title":"Blood"},{"issue":"20","key":"10.1016\/j.beha.2025.101632_bib52","doi-asserted-by":"crossref","first-page":"2246","DOI":"10.1200\/JCO.21.01676","article-title":"Long-term follow-up of combination of B-cell maturation antigen and CD19 chimeric antigen receptor T cells in multiple myeloma","volume":"40","author":"Wang","year":"2022","journal-title":"J Clin Oncol"},{"issue":"4","key":"10.1016\/j.beha.2025.101632_bib53","doi-asserted-by":"crossref","first-page":"1357","DOI":"10.1111\/cas.14799","article-title":"Preclinical and clinical advances in dual\u2010target chimeric antigen receptor therapy for hematological malignancies","volume":"112","author":"Guo","year":"2021","journal-title":"Cancer Sci"},{"key":"10.1016\/j.beha.2025.101632_bib54","article-title":"Oncolytic herpes simplex virus delivery of dual CAR targets of CD19 and BCMA as well as immunomodulators to enhance therapeutic efficacy in solid tumors combined with CAR T cell therapy","volume":"12","author":"Liu","year":"2022","journal-title":"Front Oncol"},{"issue":"2","key":"10.1016\/j.beha.2025.101632_bib55","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1158\/2643-3230.BCD-22-0074","article-title":"Anti-BCMA\/CD19 CAR T cells with early immunomodulatory maintenance for multiple myeloma responding to initial or later-line therapy","volume":"4","author":"Alfred","year":"2023","journal-title":"Blood Cancer Discov"},{"issue":"1","key":"10.1016\/j.beha.2025.101632_bib56","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1186\/s13046-021-02214-z","article-title":"High efficacy and safety of CD38 and BCMA bispecific CAR-T in relapsed or refractory multiple myeloma","volume":"41","author":"Tang","year":"2022","journal-title":"J Exp Clin Cancer Res"},{"key":"10.1016\/j.beha.2025.101632_bib57","article-title":"Prolonged hematological toxicity in patients receiving BCMA\/CD19 CAR-T-cell therapy for relapsed or refractory multiple myeloma","volume":"13","author":"Li","year":"2022","journal-title":"Front Immunol"},{"issue":"20","key":"10.1016\/j.beha.2025.101632_bib58","doi-asserted-by":"crossref","first-page":"2246","DOI":"10.1200\/JCO.21.01676","article-title":"Long-term follow-up of combination of B-cell maturation antigen and CD19 chimeric antigen receptor T cells in multiple myeloma","volume":"40","author":"Wang","year":"2022","journal-title":"J Clin Oncol"},{"issue":"1","key":"10.1016\/j.beha.2025.101632_bib59","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1038\/s41375-023-02065-x","article-title":"Bispecific CS1-BCMA CAR-T cells are clinically active in relapsed or refractory multiple myeloma","volume":"38","author":"Li","year":"2024","journal-title":"Leukemia"},{"issue":"1","key":"10.1016\/j.beha.2025.101632_bib60","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1186\/s13045-021-01170-7","article-title":"A bispecific CAR-T cell therapy targeting BCMA and CD38 in relapsed or refractory multiple myeloma","volume":"14","author":"Mei","year":"2021","journal-title":"J Hematol Oncol"},{"issue":"11","key":"10.1016\/j.beha.2025.101632_bib61","article-title":"Both APRIL and antibody-fragment-based CAR T cells for myeloma induce BCMA downmodulation by trogocytosis and internalization","volume":"10","author":"Nicolas","year":"2022","journal-title":"J Immunother Cancer"},{"issue":"7","key":"10.1016\/j.beha.2025.101632_bib62","doi-asserted-by":"crossref","first-page":"746","DOI":"10.1182\/blood-2017-05-781351","article-title":"An APRIL-based chimeric antigen receptor for dual targeting of BCMA and TACI in multiple myeloma","volume":"131","author":"Lydia","year":"2018","journal-title":"Blood"},{"issue":"7","key":"10.1016\/j.beha.2025.101632_bib63","doi-asserted-by":"crossref","first-page":"811","DOI":"10.1016\/S1470-2045(23)00246-2","article-title":"\u03b3-Secretase inhibitor in combination with BCMA chimeric antigen receptor T-cell immunotherapy for individuals with relapsed or refractory multiple myeloma: a phase 1, first-in-human trial","volume":"24","author":"Andrew","year":"2023","journal-title":"Lancet Oncol"},{"issue":"2","key":"10.1016\/j.beha.2025.101632_bib64","first-page":"568","article-title":"All-trans retinoic acid works synergistically with the \u03b3-secretase inhibitor crenigacestat to augment BCMA on multiple myeloma and the efficacy of BCMA-CAR T cells","volume":"108","author":"Estefan\u00eda","year":"2023","journal-title":"Haematologica"},{"issue":"2","key":"10.1016\/j.beha.2025.101632_bib65","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1007\/s40259-016-0165-6","article-title":"Management of multiple myeloma with second-generation antibody-drug conjugates","volume":"30","author":"Robak","year":"2016","journal-title":"BioDrugs"},{"issue":"1","key":"10.1016\/j.beha.2025.101632_bib66","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1186\/s40164-025-00632-9","article-title":"Antibody-drug conjugates in breast cancer: current evidence and future directions","volume":"14","author":"Li","year":"2025","journal-title":"Exp Hematol Oncol"},{"issue":"14","key":"10.1016\/j.beha.2025.101632_bib67","doi-asserted-by":"crossref","first-page":"3192","DOI":"10.1002\/cncr.32909","article-title":"The BiTE (bispecific T-cell engager) platform: development and future potential of a targeted immuno-oncology therapy across tumor types","volume":"126","author":"Hermann","year":"2020","journal-title":"Cancer"},{"issue":"8","key":"10.1016\/j.beha.2025.101632_bib68","doi-asserted-by":"crossref","first-page":"1025","DOI":"10.1080\/14712598.2021.1872540","article-title":"An update on B-cell maturation antigen-targeted therapies in Multiple Myeloma","volume":"21","author":"Martino","year":"2021","journal-title":"Expet Opin Biol Ther"},{"issue":"Supple 1","key":"10.1016\/j.beha.2025.101632_bib69","article-title":"Long-term follow-up of real-world teclistamab therapy for relapsed\/refractory multiple myeloma from the IMWG immunotherapy working group committee","volume":"144","author":"Tan","year":"2024","journal-title":"Blood"},{"issue":"1","key":"10.1016\/j.beha.2025.101632_bib70","doi-asserted-by":"crossref","first-page":"6154","DOI":"10.1038\/s41598-022-09964-6","article-title":"Author Correction: combination gemcitabine and PD-L1xCD3 bispecific T cell engager (BiTE) enhances T lymphocyte cytotoxicity against cholangiocarcinoma cells","volume":"12","author":"Methi","year":"2022","journal-title":"Sci Rep"},{"issue":"5","key":"10.1016\/j.beha.2025.101632_bib71","doi-asserted-by":"crossref","first-page":"1251","DOI":"10.1016\/j.ymthe.2020.02.016","article-title":"Oncolytic adenovirus armed with BiTE, cytokine, and checkpoint inhibitor enables CAR T cells to control the growth of heterogeneous tumors","volume":"28","author":"Caroline","year":"2020","journal-title":"Mol Ther"},{"issue":"2","key":"10.1016\/j.beha.2025.101632_bib72","doi-asserted-by":"crossref","first-page":"e120","DOI":"10.1016\/S2352-3026(24)00347-8","article-title":"Isatuximab, bortezomib, lenalidomide, and limited dexamethasone in patients with transplant-ineligible multiple myeloma (REST): a multicentre, single-arm, phase 2 trial","volume":"12","author":"Frida","year":"2025","journal-title":"Lancet Haematology"},{"issue":"6","key":"10.1016\/j.beha.2025.101632_bib73","doi-asserted-by":"crossref","first-page":"e415","DOI":"10.1016\/S2352-3026(24)00070-X","article-title":"Isatuximab, carfilzomib, lenalidomide, and dexamethasone in patients with newly diagnosed, transplantation-eligible multiple myeloma (SKylaRk): a single-arm, phase 2 trial","volume":"11","author":"Elizabeth","year":"2024","journal-title":"Lancet Haematology"},{"key":"10.1016\/j.beha.2025.101632_bib74","doi-asserted-by":"crossref","DOI":"10.1016\/j.canlet.2022.215721","article-title":"Unity brings strength: combination of CAR-T cell therapy and HSCT","volume":"549","author":"Huang","year":"2022","journal-title":"Cancer Lett"},{"issue":"16","key":"10.1016\/j.beha.2025.101632_bib75","doi-asserted-by":"crossref","first-page":"1467","DOI":"10.1056\/NEJMoa2313812","article-title":"Sequential CD7 CAR T-cell therapy and allogeneic HSCT without GVHD prophylaxis","volume":"390","author":"Hu","year":"2024","journal-title":"N Engl J Med"},{"issue":"1","key":"10.1016\/j.beha.2025.101632_bib76","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1186\/s12943-024-02032-9","article-title":"A new era of cancer immunotherapy: combining revolutionary technologies for enhanced CAR-M therapy","volume":"23","author":"Li","year":"2024","journal-title":"Mol Cancer"},{"issue":"1","key":"10.1016\/j.beha.2025.101632_bib77","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1186\/s40164-024-00549-9","article-title":"The next frontier in immunotherapy: potential and challenges of CAR-macrophages","volume":"13","author":"Li","year":"2024","journal-title":"Exp Hematol Oncol"},{"issue":"7_Supple","key":"10.1016\/j.beha.2025.101632_bib78","article-title":"Abstract 4077: dual-targeted CAR-NK cell therapy: optimized CAR design to prevent antigen escape and elicit a deep and durable response in multiple myeloma","volume":"83","author":"Yang","year":"2023","journal-title":"Cancer Res"},{"issue":"1","key":"10.1016\/j.beha.2025.101632_bib79","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1186\/s12943-023-01723-z","article-title":"CAR-cell therapy in the era of solid tumor treatment: current challenges and emerging therapeutic advances","volume":"22","author":"Karama","year":"2023","journal-title":"Mol Cancer"},{"issue":"52","key":"10.1016\/j.beha.2025.101632_bib80","article-title":"Hyperactive Rac stimulates cannibalism of living target cells and enhances CAR-M-mediated cancer cell killing","volume":"120","author":"Abhinava","year":"2023","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.beha.2025.101632_bib81","first-page":"1","article-title":"Strengthening the CAR\u2010T cell therapeutic application using CRISPR\/Cas9 technology","author":"Muhammad","year":"2021","journal-title":"Biotechnol Bioeng"},{"key":"10.1016\/j.beha.2025.101632_bib82","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2024.1354825","article-title":"Revolutionizing cancer treatment: enhancing CAR-T cell therapy with CRISPR\/Cas9 gene editing technology","volume":"15","author":"Tao","year":"2024","journal-title":"Front Immunol"},{"issue":"1","key":"10.1016\/j.beha.2025.101632_bib83","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1186\/s13046-021-02076-5","article-title":"CRISPR\/Cas9 revitalizes adoptive T-cell therapy for cancer immunotherapy","volume":"40","author":"Ghaffari","year":"2021","journal-title":"J Exp Clin Cancer Res"},{"issue":"Supple 1","key":"10.1016\/j.beha.2025.101632_bib84","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1182\/blood-2020-141115","article-title":"Efficient gene editing of CART cells with CRISPR-cas12a for enhanced antitumor efficacy","volume":"136","author":"Siegler","year":"2020","journal-title":"Blood"},{"key":"10.1016\/j.beha.2025.101632_bib85","doi-asserted-by":"crossref","first-page":"1973","DOI":"10.1182\/blood-2018-99-119514","article-title":"PD-1 inhibitor combinations as salvage therapy for relapsed\/refractory multiple myeloma (MM) patients progressing after bcma-directed CAR T cells","volume":"132","author":"Bernabei","year":"2018","journal-title":"Blood"},{"issue":"1","key":"10.1016\/j.beha.2025.101632_bib86","article-title":"The emerging landscape of novel 4-1BB (CD137) agonistic drugs for cancer immunotherapy","volume":"15","author":"Christina","year":"2023","journal-title":"mAbs"},{"issue":"1","key":"10.1016\/j.beha.2025.101632_bib87","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1186\/s13045-021-01117-y","article-title":"Dasatinib enhances anti-leukemia efficacy of chimeric antigen receptor T cells by inhibiting cell differentiation and exhaustion","volume":"14","author":"Zhang","year":"2021","journal-title":"J Hematol Oncol"},{"issue":"3","key":"10.1016\/j.beha.2025.101632_bib88","first-page":"857","article-title":"Lisocabtagene maraleucel for second-line relapsed or refractory large B-cell lymphoma: patient-reported outcomes from the PILOT study","volume":"109","author":"Leo","year":"2024","journal-title":"Haematologica"},{"issue":"19","key":"10.1016\/j.beha.2025.101632_bib89","article-title":"TOP CAR with TMIGD2 as a safe and effective costimulatory domain in CAR cells treating human solid tumors","volume":"10","author":"Christopher","year":"2024","journal-title":"Sci Adv"},{"issue":"21","key":"10.1016\/j.beha.2025.101632_bib90","doi-asserted-by":"crossref","DOI":"10.1182\/blood.V124.21.5950.5950","article-title":"Construction of the lentiviral and electric transfection vectors encoding anti-human CD30 or CD33 chimeric antigen receptor (CAR) gene and respective expression injurkat leukemia cell line","volume":"124","author":"Zeng","year":"2014","journal-title":"Blood"},{"issue":"7\u20138","key":"10.1016\/j.beha.2025.101632_bib91","article-title":"Comparative analysis and optimization of protocols for producing recombinant lentivirus carrying the anti-Her2 chimeric antigen receptor gene","volume":"20","author":"Yuan","year":"2018","journal-title":"J Gene Med"},{"issue":"1","key":"10.1016\/j.beha.2025.101632_bib92","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1016\/j.bbrc.2016.03.054","article-title":"Highly efficient gene transfer using a retroviral vector into murine T cells for p\\reclinical chimeric antigen receptor-expressing T cell Therapy","volume":"473","author":"Hotaka","year":"2016","journal-title":"Biochem Biophys Res Commun"},{"issue":"1","key":"10.1016\/j.beha.2025.101632_bib93","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1186\/s12943-023-01830-x","article-title":"Target delivery of a PD-1-TREM2 scFv by CAR-T cells enhances anti-tumor efficacy in colorectal cancer","volume":"22","author":"Chen","year":"2023","journal-title":"Mol Cancer"},{"issue":"4","key":"10.1016\/j.beha.2025.101632_bib94","doi-asserted-by":"crossref","first-page":"1552","DOI":"10.1016\/j.ymthe.2025.02.001","article-title":"Converting TCR-based chimeric antigen receptor STAR into dual-specific targeting receptor for cancer immunotherapy","volume":"33","author":"Yu","year":"2025","journal-title":"Mol Ther"},{"issue":"8","key":"10.1016\/j.beha.2025.101632_bib95","first-page":"1090","article-title":"Impact of scFv on functionality and safety of third-generation CD123 CAR T cells","volume":"12","author":"Maxime","year":"2024"},{"issue":"9","key":"10.1016\/j.beha.2025.101632_bib96","doi-asserted-by":"crossref","first-page":"2255","DOI":"10.1158\/1078-0432.CCR-16-1300","article-title":"Multiplex genome editing to generate universal CAR T cells resistant to PD1 inhibition","volume":"23","author":"Ren","year":"2017","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.beha.2025.101632_bib97","doi-asserted-by":"crossref","first-page":"737","DOI":"10.1038\/s41598-017-00462-8","article-title":"CRISPR\/Cas9-mediated PD-1 disruption enhances anti-tumor efficacy of human chimeric antigen receptor T cells","volume":"7","author":"Levi","year":"2017","journal-title":"Sci Rep"},{"issue":"8","key":"10.1016\/j.beha.2025.101632_bib98","doi-asserted-by":"crossref","first-page":"3130","DOI":"10.1172\/JCI83092","article-title":"Human CAR T cells with cell-intrinsic PD-1 checkpoint blockade resist tumor-mediated inhibition","volume":"126","author":"Leonid","year":"2016","journal-title":"J Clin Investig"},{"issue":"2","key":"10.1016\/j.beha.2025.101632_bib99","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1158\/1078-0432.CCR-20-1457","article-title":"CD19-specific CAR T cells that express a PD-1\/CD28 chimeric switch-receptor are effective in patients with PD-L1-positive B-cell lymphoma","volume":"27","author":"Liu","year":"2021","journal-title":"Clin Cancer Res"},{"issue":"Suppl 1","key":"10.1016\/j.beha.2025.101632_bib100","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1182\/blood-2020-141062","article-title":"A fully-human armored BCMA CAR boosts function of CD4+ CAR-T cells and resists TGF-\u03b2 suppression in pre-clinical models of multiple myeloma","volume":"136","author":"Alabanza","year":"2020","journal-title":"Blood"},{"issue":"1","key":"10.1016\/j.beha.2025.101632_bib101","article-title":"Weal and woe of interleukin-18 in the T cell therapy of cancer","volume":"13","author":"Christoph","year":"2025","journal-title":"Journal For Immunotherapy of Cancer"}],"container-title":["Best Practice & Research Clinical Haematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1521692625000374?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1521692625000374?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,7]],"date-time":"2025-11-07T20:39:25Z","timestamp":1762547965000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1521692625000374"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,6]]},"references-count":101,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2025,6]]}},"alternative-id":["S1521692625000374"],"URL":"https:\/\/doi.org\/10.1016\/j.beha.2025.101632","relation":{},"ISSN":["1521-6926"],"issn-type":[{"value":"1521-6926","type":"print"}],"subject":[],"published":{"date-parts":[[2025,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Research progress of targeted BCMA CAR-T therapy for relapsed\/refractory multiple myeloma antigen-negative relapse","name":"articletitle","label":"Article Title"},{"value":"Best Practice & Research Clinical Haematology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.beha.2025.101632","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"101632"}}